Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
Portfolio Pulse from Lara Goldstein
Psychedelics companies Cybin Inc. (NYSE:CYBN) and Small Pharma Inc. (OTCQB:DMTTF) have completed their acquisition agreement, making Small Pharma a wholly-owned subsidiary of Cybin. The deal is seen as a significant milestone for Cybin, positioning it as a leader in the psychedelics sector. The combined company now has the industry’s largest deuterated DMT pipeline program and a large IP portfolio in the psychedelic drug development space. The merger is expected to accelerate innovation in the industry and deliver enhanced value for shareholders.
October 23, 2023 | 5:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin's acquisition of Small Pharma positions it as a leader in the psychedelics sector with the industry’s largest deuterated DMT pipeline program. This could potentially enhance its market position and shareholder value.
The acquisition of Small Pharma by Cybin is a significant development for the company. It not only expands Cybin's portfolio but also positions it as a leader in the psychedelics sector. This could potentially enhance its market position and increase its shareholder value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Small Pharma's acquisition by Cybin could potentially enhance its market position and shareholder value.
The acquisition of Small Pharma by Cybin is a significant development for the company. It not only expands Small Pharma's reach but also positions it as a part of a leader in the psychedelics sector. This could potentially enhance its market position and increase its shareholder value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100